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ABSTRACT
Background. Patients presenting with peritoneal metas-
tases (PM) of colorectal cancer (CRC) can be curatively
treated with cytoreductive surgery (CRS) and hyperthermic
intraperitoneal chemotherapy (HIPEC). Angiogenesis is
under control of multiple molecules of which HIF1a,
SDF1, CXCR4, and VEGF are key players. We investi-
gated these angiogenesis-related markers and their
prognostic value in patients with PM arising from CRC
treated with CRS and HIPEC.
Patients and Methods. Clinicopathological data and tis-
sue specimens were collected in 2 tertiary referral centers
from 52 patients who underwent treatment for isolated PM
of CRC. Whole tissue specimens were subsequently ana-
lyzed for protein expression of HIF1a, SDF1, CXCR4, and
VEGF by immunohistochemistry. Microvessel density
(MVD) was analyzed by CD31 immunohistochemistry.
The relationship between overall survival (OS) and protein
expression as well as other clinicopathological character-
istics was analyzed.
Results. Univariate analysis showed that high peritoneal
cancer index (PCI), resection with residual disease and
high expression of VEGF were negatively correlated with
OS after treatment with CRS and HIPEC (P\ 0.01,
P\ 0.01, and P = 0.02, respectively). However, no asso-
ciation was found between the other markers and OS
(P[ 0.05). Multivariate analysis showed an independent
association between OS and PCI, resection outcome and
VEGF expression (multivariate HR: 6.1, 7.8 and 3.8,
respectively, P B 0.05).
Conclusions. An independent association was found
between high VEGF expression levels and worse OS after
CRS and HIPEC. The addition of VEGF expression to the
routine clinicopathological workup could help to identify
patients at risk for early treatment failure. Furthermore,
VEGF may be a potential target for adjuvant treatment in
these patients.
Colorectal cancer (CRC) is a major health concern in the
Western world. It is the third most common cancer
worldwide for both males and females, accounting for
more than 1 million new cases and approximately 600,000
deaths annually. In the course of their disease, roughly
25 % of these patients will develop peritoneal metastases
(PM), alone or in combination with other metastases.1–3
In CRC, isolated peritoneal metastases are regarded as a
form of localized disease spread and are thus considered
amenable to local control, i.e., surgery.4,5 PM are increasingly
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treated with curative intent, using cytoreductive surgery (CRS)
and hyperthermic intraperitoneal chemotherapy (HIPEC), as
opposed to systemic chemotherapy.6,7 Because treatment with
CRS and HIPEC has morbidity and mortality rates of 15–18 %
and 5 %, respectively, it is of utmost importance to carefully
select those patients who will benefit most from this
treatment.7–10
At present, patients are selected solely based on clinical
parameters and intraoperative findings. Based on the
hypothesis that phenotype of PM in CRC, and thus also clin-
ical behavior, is driven by underlying biological mechanisms,
readouts of disease biology (i.e., biomarkers) will aid in
establishing a more refined identification of suitable patients.
Additionally, molecular targets may be of great value in
prognosis assessment, imaging, and guidance of therapy.
Metastasis formation depends on the combined pro-
cesses of dissemination of tumor cells and development of
a receptive microenvironment. One important condition for
successful outgrowth of these tumor cells is the presence of
sufficient oxygen, aided by the formation of new blood
vessels referred to as angiogenesis.11 Angiogenesis is under
control of multiple molecules of which HIF1a, SDF1,
CXCR4, and VEGF are key players. Vascular endothelial
growth factor (VEGF) is the most important and best
characterized angiogenic factor and also the target of the
anticancer drug bevacuzimab.12 The interaction of CXCR4
and SDF1 could advance tumor progression and metastases
through the induction of VEGF-mediated angiogenesis.13
Furthermore, HIF1 is known to regulate the activation of
VEGF directly (See Supplemental Fig. 1).14,15
Expression of HIF1, CXCR4, SDF1, and VEGF have
each been reported to have clinical implications in several
malignancies, including primary CRC.16 Furthermore,
multiple studies have shown the relevance of angiogenesis,
measured by the formation of microvessels (i.e.,
microvessel density [MVD]) in CRC.17 Therefore, we
hypothesized that these molecules may serve as prognostic
markers in this population of metastasized CRC patients.
MATERIALS AND METHODS
Patients were included from 2 prospective registries. All
consecutive patients treated with curative intent with CRS
and HIPEC at the Catharina Hospital in Eindhoven from
2007 to 2010 and from the VU University Medical Center
Amsterdam from 2010 and 2011, both tertiary referral
centers for patients with peritoneal surface malignancy,
were reviewed for inclusion. Only patients presenting with
isolated PM were included for this retrospective study.
Clinicopathological data were extracted from the patient
records at both institutions. All tumors were staged
according to the fifth version of the American Joint
Committee on Cancer (AJCC) pathologic-node-metastasis
(TNM) classification.
Formalin-fixed and paraffin-embedded (FFPE) tissue
specimens obtained during CRS were collected from the
archives and hematoxylin-eosin (H&E) slides were
reviewed to verify the presence of tumor cells. Collection,
storage, and use of clinicopathological data and tissue
specimens were performed in compliance with the ‘‘Code
for Proper Secondary Use of Human Tissue in The
Netherlands.’’
Treatment—Cytoreductive Surgery and HIPEC
The preoperative workup and the CRS and HIPEC
procedure were carried out in a uniform fashion by both
surgical teams according to the Dutch protocol using the
open coliseum technique with Mitomycin C.7,18
Tissue Specimens and Immunohistochemistry Protocols
The 4-lm sections were mounted on glass slides,
deparaffinized, and rehydrated. Endogenous peroxidase
was blocked using 0.3 % hydrogen peroxide in methanol.
All consecutive slides were subsequently immunohisto-
chemically stained for all markers according to the
optimized protocols summarized in Supplementary
Table 1. All sections were counterstained with Mayer’s
hematoxylin.
Scoring was performed using a 109 objective or a
209 objective, depending on whether the staining was
cytoplasmic (109 /0.25; diameter 2.01 mm) or nuclear
(209 /0.45; diameter 0.98 mm). The intensity observed in
the neoplastic cells was subsequently scored as negative,
weak, moderate, and strong. For HIF1a, protein expression
in the nuclei of tumor cells was scored, whereas for SDF1,
CXCR4, and VEGF intensities were scored in the cyto-
plasm (Fig. 1). All tissue samples were analyzed blinded to
corresponding clinicopathological information. A second
investigator (GAM) re-evaluated 10 % of the samples in a
blinded fashion, and the samples were scored by consensus
between the first and second investigators as a quality-
control step. Intensity of the staining was subsequently
dichotomized, i.e., ‘‘low expression’’ or ‘‘high expression’’
at different cutoffs for 4 markers as shown in Table 1. All
analyses were performed using the dichotomized staining
intensity score.
As for CD31, all specimens were stained using an anti-
CD31 antibody according to an optimized protocol sum-
marized in Supplemental Table 1. Finally, the average
MVD was quantified in the peritoneal lesions using a
computerized morphometric and image analysis approach,
as previously described.19 In short, complete slides were
scanned using a digital Mirax slide Scanner system
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(3DHISTECH, Budapest, Hungary) with a 209 objective
with a numerical aperture of 0.75 and a Sony DFW-X710
Fire Wire 1/300 type progressive SCAN IT CCD (pixel size
4.65 9 4.65 lm2). The scan resolution of all images at
209 was 0.23 lm. After scanning representative areas of
the tumor deposits were annotated manually using the
Panoramic Viewer software (3D Histech) and subsequently
exported in the TIFF image format. A computerized mor-
phometric analysis of the CD31 stained slides was
executed, using ImageJ. Subsequently, the MVD was
dichotomized as ‘‘high’’ and ‘‘low’’ MVD by setting the
threshold at 27 % of the analyzed area stained for MVD, as
based on the median.
Statistical Analysis
Data analysis was performed with the Statistical Pack-
age for the Socials Sciences (SPSS Inc., Chicago IL)
version 20 for OsX. Descriptive statistics were used to
describe clinical and treatment-related factors in the cohort.
The primary endpoint was overall survival (OS), which
was defined as time (months) from date of CRS and HIPEC
to death from any cause. Survivors were censored on the
date they were last known to be alive. For analytical pur-
poses, patients surviving less than 12.6 months post-
treatment were additionally categorized as short survivors,
and patients surviving more than 12.6 months as long
survivors, based on results from the first and only ran-
domized controlled trial comparing CRS and HIPEC and
conventional chemotherapy.7
Associations between several clinicopathological variables
were tested for significance using the unpaired t test or the
Mann–Whitney U test (association between dichotomous and
continuous variable, either distributed normally or not nor-
mally), and the Chi square test for unpaired ordinal and
categorical data. Associations between marker expression and
clinicopathological variables were analyzed using the Chi
square, Kruskal–Wallis or Mann–Whitney U test, depending
on the type of variables analyzed. Survival was analyzed using
the Kaplan–Meier method. Additionally, established clinico-
pathological variables were included in a multivariate Cox
regression analysis to determine the independent effect of
each variable. Input variables were all first tested in a uni-
variate fashion for association with OS, and only significant
terms were included in the multivariate model (multivariate
Cox regression analysis). The variable selection in the mul-
tivariate Cox model was carried out using backward selection
with a threshold p value for exclusion that was set at 0.1.
A p value B0.05 was considered statistically significant.
All data reported was REMARK compliant.20
RESULTS
The initial study cohort consisted of 53 patients. One
patient was lost to follow-up. The patient characteristics
are summarized in Table 1.
The median survival for the entire cohort (n = 52) was
26 months (Supplemental Fig. 2). A total of 25 events were
recorded at the end of follow-up. Univariate analysis showed
a1b1 c1 d1
b2 c2 d2
b3 c3 d3
a2
a3
VEGFHIF1α SDF1 CXCR4
FIG. 1 Expression pattern of a HIF1a, b SDF1, c CXCR4, and d
VEGF staining in peritoneal metastases of colorectal cancer epithe-
lium. Immunohistochemical staining patterns ranged from weak to
strong epithelial (nucleus and cytoplasm) staining for all 4 markers.
Representative examples of all stainings, ranging from weak (1) to
strong (3) in peritoneal metastases epithelium are shown
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that tumor burden (simplified Peritoneal Cancer index, sPCI)
and resection outcome were negatively correlated with sur-
vival after treatment (Supplemental Table 2).21
Nine patients were excluded for technical reasons (loss
of tissue stained for CXCR4, SDF1, VEGF and CD31
respectively), while for HIF1a ten patients were lost for the
same reason. Thus, for final marker analysis 42 patients
remained for analysis of HIF1a and 43 patients remained
for the analysis of SDF1, CXCR4 and VEGF. For MVD
analysis (CD31) data was available from 36 cases
(Table 2).
An association was noted between a high HIF1a
expression and favorable resection outcome (p = 0.03) and
male gender and higher CXCR4 expression (p = 0.01) No
association was seen between expression levels of HIF1a,
CXCR4, SDF1, VEGF, and MVD with the (other) clini-
copathological characteristics listed in Table 1 (p[ 0.05,
data not shown). In addition, there was no association
between the expression of the 4 markers and the MVD
(p[ 0.05, data not shown).
A total of 21 events occurred during follow-up in the
group of patients successfully analyzed for protein expres-
sion. Only for VEGF a significant difference in overall
survival between groups with high versus low expression
was observed (mean OS 23.8 months versus 36.1 months,
respectively, p = 0.02) (Fig. 2). For HIF1a, CXCR4, SDF1,
and MVD, there was no significant association between
protein expression and OS (p[ 0.05) (Fig. 2).
In addition, expression for VEGF was associated with
short and long survival after treatment with CRS and
HIPEC (p = 0.02). This was not the case for the other 4
markers HIF1a, SDF1, CXCR4, and MVD (p[ 0.05).
In the multiple regression analysis, it was found that
sPCI, resection outcome and VEGF expression (high ver-
sus low expression) were significant independent predictors
of survival (p = 0.02, p = 0.05, p = 0.008, respectively).
High VEGF expression had a hazard ratio of 3.8 (95 % CI
1.41–10.06), indicating an autonomous association
between VEGF expression and OS (Table 3).
DISCUSSION
Isolated peritoneal metastases are increasingly being
treated with curative intent by CRS and HIPEC, and with
TABLE 1 Patient and tumor characteristics
Total number of patients N %
Gender
Male 23 43.4 %
Female 30 56.6 %
Age (mean ? SD) 58 years SD 12.0 years
Follow-up (median, range) 22.5 months 0–59 months
Location primary tumor
Colon, including appendix 39 73.6 %
Rectosigmoid 8 15.1 %
Rectum 5 9.4 %
Double tumor 1 1.9 %
Tumor type
Adenocarcinoma 33 62.3 %
Mucinous adenocarcinoma 16 30.2 %
Signet-cell carcinoma 4 7.5 %
T classification of primary tumor
T1 1 1.9 %
T2 1 1.9 %
T3 23 43.4 %
T4 28 52.8 %
Lymph node status primary tumor
Negative 13 24.5 %
Positive 39 73.6 %
Unknown 1 1.9 %
Timing peritoneal metastases
Synchronous 30 56.6 %
Metachronous 23 43.4 %
Simplified Peritoneal Cancer Index
\2 1 1.9 %
2–4 32 60.4 %
5 11 20.8 %
[5 5 9.4 %
Unknown 4 7.5 %
Resection outcome
R0/R1 47 88.7 %
R2 6 11.3 %
Chemotherapy after CRS and HIPEC
Yes 36 67.9 %
No 13 24.5 %
Unknown 4 7.5 %
TABLE 2 Low versus high expression of HIF1a, SDF1, CXCR4,
VEGF, and MVD
Antigen Low expression High expression
HIF1a Negative, N = 0
Weak, N = 13 (31.0 %)
Moderate, N = 15 (35.7 %)
Strong, N = 14 (33.3 %)
SDF1 Negative, N = 0
Weak, N = 3 (7.0 %)
Moderate, N = 12 (27.9 %)
Strong, N = 28 (65.1 %)
CXCR4 Negative, N = 0
Weak, N = 2 (4.7 %)
Moderate, N = 16 (37.2 %)
Strong, N = 25 (58.1 %)
VEGF Negative, N = 0
Weak, N = 3 (7.0 %)
Moderate, N = 19 (44.2 %)
Strong, N = 21 (48.8 %)
MVD Low, N = 19 (52.8 %) High, N = 17 (47.2 %)
1604 E. M. V. de Cuba et al.
good clinical results.22,23 However, known clinical factors
alone appear to be insufficiently discriminatory for patient
selection, as patients are often observed presenting with
rapid recurrence after treatment despite having seemingly
favorable prognostic clinical profile. The present study
revealed an independent association between high VEGF
expression levels and worse survival after CRS and
HIPEC. The possible addition of VEGF expression to the
routine pathological workup could therefore potentially aid
in identifying those patients at risk for early treatment
failure despite their seemingly favorable clinical profile.
In addition, a correlation was noted between high
expression of CXCR4 and male gender. Data in published
literature on correlation between gender and CXCR4
expression are scarce and conflicting and thus remain
inconclusive.24,25 Interestingly, we also found an associa-
tion between high HIF1a expression and a more favorable
resection outcome. One explanation, albeit speculative,
could be that HIF1a competent tumor cells, i.e., with a
relatively high HIF1a expression, behave less aggressively
under hypoxic conditions than HIF1 negative tumor cells,
because they are still dependent on the blood supply from
blood vessels and have not yet (fully) developed the
capacity to survive under such circumstances.26–29 This
could also explain the tendency observed toward better OS
for patients with high expression of HIF1a (Fig. 2).
Besides the biological connection between these mole-
cules, expression of HIF1a, CXCR4, SDF1, and VEGF
have each been reported to have clinical implications in
several malignancies. Both lack of HIF1a expression under
hypoxic circumstances and overexpression have been pre-
viously linked to tumor progression, aggressive biological
behavior, and patient prognosis in several types of carci-
nomas.26–31 CXCR4 is the most common chemokine
expressed in tumors such as ovarian, breast, and colorectal
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FIG. 2 Kaplan-Meier curves showing the correlation between high and low expression of respectively, a HIF1a, b SDF1, c CXCR4, d VEGF,
and e MVD and overall survival in patients undergoing curative CRS and HIPEC for the treatment of PM of CRC
TABLE 3 Multivariate analysis of overall survival for the complete
CRS and HIPEC cohort (N = 52)
Variable Hazard
ratio
95 % CI p value
Simplified Peritoneal Cancer
Index
0.02
2–4 abdominal regions affected 1.00 (ref) –
5 abdominal regions affected 3.01 1.04–8.72
5–7 abdominal regions affected 6.06 1.28–
28.70
Resection outcome 0.05
No residual tumor 1.00 (ref) –
Residual tumor\2.5 mm 2.51 0.77–8.20
Residual tumor[2.5 mm 7.69 1.50–
28.70
VEGF expression 3.76 1.41–
10.06
\0.01
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cancer. Its ligand, SDF1, has been described as highly
expressed in metastatic sites, such as the lung, lymph
nodes, and liver, and has been correlated with grade and
prognosis in renal cell and breast carcinoma.32,33 The
prognostic value of high levels of VEGF has been
demonstrated in multiple solid tumors and is associated
with metastasis in CRC.34 In addition, VEGF levels have
been reported to predict survival in patients with carcino-
matosis arising from several malignancies.35–37
While in the present study VEGF expression levels
appeared to have prognostic relevance, such an association
was not observed for HIF1a, SDF1, and CXCR4 in the
present cohort. On one hand, this may look counterintu-
itive, as VEGF is regulated by HIF1a, just like SDF1 and
CXCR4, but on the other hand these regulatory networks
in vivo are subject to many interactions and apparently in
PM, other regulation mechanisms, including oncogenes, of
VEGF expression prevail over HIF1a. In fact, the lack of
prognostic significance of both SDF1 and CXCR4 in the
present study may be consistent with this observation.16,38
The current finding is also consistent with several other,
both preclinical and clinical studies on PM arising from
several epithelial malignancies such as ovarian carcinoma
in which VEGF has been shown to play a role in PM and
prognosis.35,39–47 Several studies have assessed the effect
of blocking VEGF both on ascites formation and PM for-
mation and progression.39,41,43,44,46–49 All these studies
show that blocking VEGF diminishes both ascites and PM
and thus improves survival after surgical treatment. Most
of these studies are preclinical, and there are currently no
clinical trials specifically addressing the effect of systemic
treatment in peritoneal cancer patients. However, a sub-
group analysis of clinical trials proving the efficacy of
bevacizumab added to standard chemotherapy in the pal-
liative treatment of metastatic CRC suggested that
bevacizumab may also be beneficial for peritoneal cancer
patients.50,51 Similar results were retrieved in a population-
based study.51 These findings have been supported by a
recent study, in which 16 % of patients received neoadju-
vant treatment including bevacizumab. In this study, the
addition of bevacizumab was an independent, favorable
prognostic factor for OS after CRS and HIPEC.52 These
findings, as well as evaluation of possible side effects,
await further validation. In a recent study, carried out
specifically in the CRS and HIPEC population, one group
described the early postoperative major morbidity rate to
be significantly higher after the administration of beva-
cizumab prior to CRS and HIPEC in a cohort consisting of
182 patients, of which 80 received bevacizumab.53 How-
ever, in a meta-analysis including more than 3000 patients
treated with bevacizumab in metastatic CRC the authors
concluded the therapy to be effective and the amount and
severity of reported adverse effects to be acceptable.9
In addition to utilizing VEGF as a treatment target, it
can also be used in the improvement of current preopera-
tive and intraoperative imaging. Encouraging results have
been reported on the use of specific VEGF tracers (e.g.,
89Zr-Bevacizumab), which can be used for the visualiza-
tion of VEGF expression in vivo. These interesting and
ground-breaking developments could signal a new era in
which the expression of certain molecules, e.g., VEGF,
could aid not only in the treatment of our patients, but also
in giving the treating CRS and HIPEC surgeon the much
needed edge in the operating room by better visualization
of even the smallest of tumor deposits.54–56 Despite limi-
tations of our study such as a limited sample size, we
believe the results shown are an important step toward
furthering our knowledge of the molecular landscape of
PM of CRC. The evidence gathered from (pre-)clinical
studies indicate that VEGF expression possibly plays an
important role in the pathogenesis of PM. In addition
VEGF can be targeted with specific antibodies, and these
can also be labeled to improve visualization, both preop-
eratively and intraoperatively. This increasing evidence
supports the notion that this oncogenic pathway deserves
further study in this subgroup of metastatic CRC patients.
In conclusion, high expression of VEGF was frequently
observed in PM of CRC and in the present cohort higher
VEGF expression levels correlated with worse overall sur-
vival after curative CRS and HIPEC. This may indicate that
VEGF expression may not only serve as a prognostic marker,
but also that adding anti-VEGF antibody based therapies,
i.e., bevacizumab, could have additional therapeutic value in
this subgroup of metastatic colorectal cancer patients.
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